Safety and Efficacy of Sintilimab(S) in Combination With Histone Deacetylase Inhibitor (Chidamide, C) in Newly Diagnosed Extranodal Natural Killer Cell/T-cell Lymphoma(EN): A Single-arm, Multicenter Phase II Study(SCENT-2)
Latest Information Update: 20 Apr 2022
At a glance
- Drugs Sintilimab (Primary) ; Tucidinostat (Primary) ; Gemcitabine; Oxaliplatin; Pegaspargase
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- Acronyms SCENT-2
- 06 Apr 2022 Status changed from not yet recruiting to recruiting.
- 14 Dec 2021 Results of exploratory study to investigate the efficacy and safety of Sintilimab plus Chidamide(SC) for patients with newly diagnosed ENKTLpresented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 13 Aug 2021 New trial record